Shares of Zoetis have been roughly average performers over the past decade. The shares seem appealingly valued at recent ...

Despite Zoetis' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish ...

Animal health company Zoetis (NYSE:ZTS) reported in Q2 CY2025, with sales up 4.2% year on year to $2.46 billion. The company ...

Zoetis stock reversed Tuesday, sinking into the red, despite beating second-quarter expectations as Librela sales continued ...

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and ...

The reality is that people and animals will always need medicine, treatments, and other products to live long and comfortable ...

Zoetis has been growing at a solid pace (~10% per year), and this will be the case for the foreseeable future. A steadily growing pet and livestock healthcare market will bring a nice tailwind.

Meanwhile, the company has an impeccable dividend program. The company has increased its payouts by 502% over the past decade ...

From supporting identification of certain cell characteristics to complementing clinical expertise with remote pathologist ...

Debt Management: Zoetis's debt-to-equity ratio surpasses industry norms, standing at 1.45. This suggests the company carries a substantial amount of debt, posing potential financial challenges.

Breed Explorer offers veterinarian-approved, science-backed insights to help current and prospective pet owners make informed ...

Finally, Zoetis is a dividend-paying stock, with a recent dividend yield of 1.3%. That may not seem like much, but the total annual payout, recently $1.93 per share, is up from $1.30 in 2022 and ...